Amendments to the claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

Claims 1-17 (Canceled)

Claim 18 (New). A method for the diagnosis of sepsis in a human patient comprising:

(a) obtaining a blood, plasma, or serum sample from said patient; and

(b) determining the presence and amount of human carbamoyl phosphate synthetase 1 (CPS 1) (SEQ ID NO:6) in said sample,

wherein an elevated concentration of CPS 1 protein is indicative of sepsis.

Claim 19 (New). The method of Claim 18, further comprising determining the presence and amount of:

(a) fragments of human CPS 1 (SEQ ID NO:6) having a molar mass of 200 kDa $\pm$ 50 kDa; and/or

(b) human CPS 1 (SEQ ID NO:6) derived components having a molar mass of from 68 to 70 kDa $\pm$ 3 kDa and isoelectric points in a range from 5.5 to 6.1 in said sample,

wherein an elevated concentration of human CPS 1, or said fragments or components thereof, is indicative of sepsis.

Claim 20 (New). The method according to Claim 18, wherein the presence and amount of human CPS 1 protein is determined by an immunodiagnostic assay.

Claim 21 (New). The method of Claim 20, wherein the immunodiagnostic assay is a sandwich assay.

Claim 22 (New). The method according to Claim 20, wherein said method comprises using one or more antibody that specifically recognizes the N-terminal portion of human CPS 1 consisting of amino acids 1-630 of SEQ ID NO:6.

Claim 23 (New). The method according to Claim 22, wherein the one or more antibody binds a sequence chosen from SEQ ID NO.:1, SEQ ID NO.:2, SEQ ID NO.:3, SEQ ID NO.:4, SEQ ID NO.:5, SEQ ID NO.:7 and SEQ ID NO.:8.

Claim 24 (New). The method of claim 23, wherein the antibodies are produced from a protein chosen from SEQ ID NO:7 and SEQ ID NO:8.

Claim 25 (New). The method according to Claim 18, wherein the presence and amount of CPS 1 protein is determined by the CPS 1 enzyme activity.

Claim 26 (New). The method according to Claim 18, wherein step (b) alternatively comprises: performing a multi-parameter determination, wherein the presence and amount of human carbamoyl phosphate synthetase 1 (CPS 1) (SEQ ID NO:6) is co-determined with at least one other sepsis marker.

Claim 27 (New). The method according to Claim 26, wherein the at least one other sepsis marker is chosen from procalcitonin, cancer antigen 19-9 (CA 19-9), cancer antigen 125 (CA 125), protein S100B, protein S100 A, soluble cytokeratin fragments, inflammin peptide, calcitonin-homologue peptide (CHP), the LIM, actin, and SH3 domain protein-1 (LASP-1), peptide prohormone immunoreactivity, and C-reactive protein (CRP).

Claim 28. The method of Claim 27, wherein the soluble cytokeratin fragments are chosen from soluble cytokeratin-19 fragments (CYFRA 21), a soluble cytokeratin-18 fragment known as polypeptide specific antigen (TPS), and soluble cytokeratin-1 fragments (sCY1 F).

Claim 29 (New). The method according to Claim 26, wherein the multi-parameter determination is carried out as a simultaneous determination by means of a chip technology measuring device or of an immunochromatographic measuring device.

Claim 30 (New). The method according to Claim 29, wherein said measuring device provides a complex measured result that is evaluated with the aid of a computer program.

Claim 31 (New). The method of claim 18 further comprising determining the severity of sepsis on the basis of the concentration of CPS 1, wherein the greater the concentration of CPS 1, the greater the severity of sepsis.